One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate
M.C.Garassino1†M.Vyas2†E.G.E.de Vries3R.Kanesvaran4R.Giuliani5S.Peters6European Society for Medical Oncology
Targeting B cells in pancreatic adenocarcinoma: does RESOLVE resolve the question?
P.A.Philip123
Claudin 18.2—a FAST-moving target in gastric cancer?
A.AthaudaI.Chau
Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer
T.E.Stinchcombe
Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy
E.C.Smyth1†V.Gambardella23†A.Cervantes23‡T.Fleitas23‡
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
M.Tempero1D.-Y.Oh2J.Tabernero3M.Reni4E.Van Cutsem5A.Hendifar6D.-T.Waldschmidt7N.Starling8J.-B.Bachet9H.-M.Chang10J.Maurel11R.Garcia-Carbonero12S.Lonardi13L.M.Coussens14L.Fong1L.C.Tsao15G.ColeJr16D.James17T.Macarulla3
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
U.Sahin123Ö.Türeci34G.Manikhas5F.Lordick6A.Rusyn7I.Vynnychenko8A.Dudov9I.Bazin10I.Bondarenko11B.Melichar12K.Dhaene13K.Wiechen14C.Huber134D.Maurus15A.Arozullah16J.W.Park16M.Schuler17†S.-E.Al-Batran18â€
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs
E.Felip1A.T.Shaw2A.Bearz3D.R.Camidge4B.J.Solomon5J.R.Bauman6T.M.Bauer7S.Peters8F.Toffalorio9A.Abbattista9H.Thurm10G.Peltz11R.Wiltshire12B.Besse1314
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆
D.R.Spigel1D.Vicente2T.E.Ciuleanu3S.Gettinger4S.Peters5L.Horn6C.Audigier-Valette7N.Pardo Aranda8O.Juan-Vidal9Y.Cheng10H.Zhang11M.Shi12A.Luft13J.Wolf14S.Antonia15†K.Nakagawa16J.Fairchild17†C.Baudelet18…M.Reck22
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy
L.Du1C.Yau2L.Brown-Swigart3R.Gould1G.Krings3G.L.Hirst2I.Bedrosian4R.M.Layman5J.M.Carter6M.Klein7S.Venters2S.Shad2M.van der Noordaa2A.J.Chien8T.Haddad9C.Isaacs10L.Pusztai11K.Albain12…W.F.Symmans121
A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
A.Brufsky1S.B.Kim2Ž.Zvirbule3A.Eniu4†J.Mebis5J.H.Sohn6M.Wongchenko7S.Chohan8R.Amin7Y.Yan7V.McNally9D.Miles10S.Loi11
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
D.J.McGrail1P.G.Pilié2N.U.Rashid34L.Voorwerk5M.Slagter678M.Kok59E.Jonasch2M.Khasraw10A.B.Heimberger11B.Lim12N.T.Ueno12J.K.Litton12R.Ferrarotto13J.T.Chang1415S.L.Moulder12S.-Y.Lin1
Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey
J.Barrière1J.Gal2B.Hoch3O.Cassuto4A.Leysalle1E.Chamorey2D.Borchiellini5
Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19
C.TrojanielloM.G.VitaleP.A.Ascierto
Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients who underwent antiestrogenic therapy
M.Montopoli123†M.Zorzi4†V.Cocetta1T.Prayer-Galetti5S.Guzzinati4E.Bovo4M.Rugge46A.Calcinotto37
Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry
D.H.Kwon1R.Vashisht23H.T.Borno12R.R.Aggarwal12E.J.Small12A.J.Butte23F.W.Huang1234
Combined small-cell lung carcinoma revealed to be an intratumoural metastasis by genetic analysis
K.D.Lach1M.Sorin2C.Huynh2N.S.Alirezaie34A.Fiore23B.Fiset3R.F.Rayes25S.Camilleri-Broet1R.Fraser1J.Majewski34J.D.Spicer5L.A.Walsh23P.O.Fiset1
Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient
R.K.Hastings1†M.R.Openshaw1†M.Vazquez2A.B.Moreno-Cardenas3D.Fernandez-Garcia1L.Martinson1K.Kulbicki1L.Primrose1D.S.Guttery1K.Page1B.Toghill1C.Richards4A.Thomas1J.Tabernero35R.C.Coombes6S.Ahmed4R.A.Toledo35†J.A.Shaw1â€
High incidence of CDA deficiency in patients with hematological malignancies: perspectives and therapeutic implications
M.Donnette1J.Ciccolini1C.Pissier2R.Costello3F.Duffaud4S.Salas4L.Farnault3A.Tichadou3R.Arcani5P.A.Jarrot5L.H.Ouafik2G.Venton3R.Fanciullino1
VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data
S.Peters1U.Dafni2M.Perol3E.Felip4L.Polito5N.Pal6T.G.N.Ton6D.Merritt7S.Morris8R.A.Stahel9
